Tacrolimus is a small molecule commercialized by TFF Pharmaceuticals, with a leading Phase II program in Lung Transplant Rejection. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Tacrolimus’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Tacrolimus is expected to reach an annual total of $11 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Tacrolimus Overview

Tacrolimus is under development for the treatment of lung transplant rejection. and severe asthma. It is a dry powder inhalation (DPI) administered through Inhalational route. It acts by targeting Calcineurin. The drug candidate is being developed based on the Thin Film Freezing (TFF) technology platform.

TFF Pharmaceuticals Overview

TFF Pharmaceuticals is a biopharmaceutical company that develops and commercializes inhalable solutions to treat respiratory diseases. The company is investigating TFF VORI, an inhaled dry powder drug targeting invasive pulmonary aspergillosis (IPA); TFF TAC-LAC, an inhaled dry powder used with an inhaler; and vaccines for influenza, ebola, Marburg, and alphaviruses. The company is also evaluating a dry powder formulation of Niclosamide against COVID-19. It utilizes its proprietary thin film freezing (TFF) technology platform to improve the solubility of poorly water-soluble drugs and reduce side effects. TFF Pharmaceuticals is headquartered in Austin, Texas, the US.
The company reported revenues of (US Dollars) US$0.5 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$0.1 million in FY2021. The operating loss of the company was US$31.8 million in FY2022, compared to an operating loss of US$31.8 million in FY2021. The net loss of the company was US$31.8 million in FY2022, compared to a net loss of US$31 million in FY2021. The company reported revenues of US$0.2 million for the third quarter ended September 2023, a decrease of 29.6% over the previous quarter.

For a complete picture of Tacrolimus’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.